Posted on 9/29/20
Lowe's Looks Poised To Keep Going Higher
SummaryThe junior member of a home improvement retailing duopoly, LOW is being transformed under new leadership.LOW's turnaround has parallels with that of UPS, with both following . . .
Posted on 2/14/20
Merck Spins, And Falls: Why I Am More Bullish Than The Street
SummaryMRK has gone into a tailspin since its Q4 conference call.It reported a fair but not great Q4, and surprised and disappointed the Street with a . . .
Posted on 11/19/19
Regeneron Rebounds Again: A Progress Report
SummaryREGN reported a strong Q3, with Eylea beating expectations, helped at least a little by spot shortages of re-compounded Avastin.The stock has reacted well, rejoining the . . .
Posted on 11/18/19
Regeneron Rebounds Again: A Progress Report
SummaryREGN reported a strong Q3, with Eylea beating expectations, helped at least a little by spot shortages of re-compounded Avastin.The stock has reacted well, rejoining the . . .
Posted on 10/31/19
Merck: Raising My Fair Value Estimate Once Again
Summary MRK reported a great sales effort in Q3, marred only by a writedown that the Street is ignoring. Keytruda is demonstrating amazing sales momentum, and . . .
Posted on 10/31/19
Merck: Raising My Fair Value Estimate Once Again
SummaryMRK reported a great sales effort in Q3, marred only by a writedown that the Street is ignoring.Keytruda is demonstrating amazing sales momentum, and looks to . . .
Posted on 10/24/19
Biogen: A Trading Strategy
SummaryBIIB surprised the Street with news that it plans to file a BLA for aducanumab, or adu, in Q1 2020.Separately, BIIB reported upside EPS surprise for . . .
Posted on 4/23/19
Honeywell Shrinks To Grow: The Case For More Alpha
Summary HON spun off 20% of sales in two actions in H2 last year, but the market cap loss was minimal. The company may do further . . .
Posted on 4/23/19
Honeywell Shrinks To Grow: The Case For More Alpha
SummaryHON spun off 20% of sales in two actions in H2 last year, but the market cap loss was minimal.The company may do further spins going . . .
Posted on 4/1/19
Thoughts On A Post-Merger Bristol-Myers Squibb: Scaling From Celgene To Buy BMS
Summary CELG appears to be about to become a BMY asset, based on end-of-week news flow. The surge in CELG shares and drop in BMY below . . .
Posted on 4/1/19
Thoughts On A Post-Merger Bristol-Myers Squibb: Scaling From Celgene To Buy BMS
Summary CELG appears to be about to become a BMY asset, based on end-of-week news flow. The surge in CELG shares and drop in BMY below . . .
Posted on 4/1/19
Thoughts On A Post-Merger Bristol-Myers Squibb: Scaling From Celgene To Buy BMS
SummaryCELG appears to be about to become a BMY asset, based on end-of-week news flow.The surge in CELG shares and drop in BMY below $48 lead . . .
Posted on 3/6/19
If The Celgene Deal Fails, Who Would Buy Bristol-Myers Squibb?
Summary BMY is planning to acquire CELG, but critics have emerged, often saying that BMY should sell itself. However, it is not clear to me that . . .
Posted on 3/6/19
If The Celgene Deal Fails, Who Would Buy Bristol-Myers Squibb?
Summary BMY is planning to acquire CELG, but critics have emerged, often saying that BMY should sell itself. However, it is not clear to me that . . .
Posted on 3/6/19
If The Celgene Deal Fails, Who Would Buy Bristol-Myers Squibb?
SummaryBMY is planning to acquire CELG, but critics have emerged, often saying that BMY should sell itself.However, it is not clear to me that many companies . . .
Posted on 2/8/19
Vertex: Shareholders Might Have Reason To Breathe More Easily
SummaryVertex Pharmaceuticals has announced positive efficacy and tolerability results for the first of its two 3-drug candidates for cystic fibrosis.I expect FDA approval of whichever combo . . .
Posted on 1/28/19
BMS Reports Q4: Analysis Of Its Stock And Of Celgene
Summary Bristol-Myers Squibb reported a solid Q4 and pretty good guidance for 2019, but revenue growth is slowing. In that context and given poor new drug . . .
Posted on 1/28/19
BMS Reports Q4: Analysis Of Its Stock And Of Celgene
SummaryBristol-Myers Squibb reported a solid Q4 and pretty good guidance for 2019, but revenue growth is slowing.In that context and given poor new drug development the . . .
Posted on 12/21/18
Johnson & Johnson: Buy The Dip? A 2-Point Analysis
Summary JNJ shares were doing well this year as investors bought Big Pharma, then got hit on a Reuters article. I have reviewed JNJ's product liability . . .
Posted on 12/21/18
Johnson & Johnson: Buy The Dip? A 2-Point Analysis
SummaryJNJ shares were doing well this year as investors bought Big Pharma, then got hit on a Reuters article.I have reviewed JNJ's product liability issues before . . .
Posted on 11/7/18
Regeneron Reports Q3: Updating Its Growth Prospects
SummaryREGN has been providing a lot of news on important products lately.It announced earnings Tuesday, which were solid, but Eylea growth has slowed.In this update on . . .
Posted on 11/2/18
Evaluating Pfizer's Growth Plans And Valuation
Summary PFE had a mild downside reaction to a minimal miss on Q3 sales. But the stock remains in an uptrend, having increased its price:sales ratio . . .
Posted on 11/2/18
Evaluating Pfizer's Growth Plans And Valuation
SummaryPFE had a mild downside reaction to a minimal miss on Q3 sales.But the stock remains in an uptrend, having increased its price:sales ratio from 4X . . .
Posted on 8/23/18
TJX: Not Maxxed Out
SummaryTJX, best known for TJ Maxx, Marshall's, and HomeGoods, reported a beat-and-raise Q2 Tuesday.The stock, which had been strong coming into the report, surged to new . . .
Posted on 7/5/18
JPMorgan And Dimon's 'Golden Age Of Banking' - An Assessment
Introduction - The case for a golden age of bankingOne of the most interesting interviews with a corporate leader I have seen in some time was . . .
Posted on 6/12/18
Cigna-Express Scripts: Analysis Of Each Stock And Of The Deal
Background: The top-down case for a fresh look at healthcare middlemenA theme I've had since February has been to look for anti-momentum stocks. Simple translation: depressed . . .
Posted on 4/19/18
Johnson & Johnson: Going The Way Of IBM?
As a long-only investor, it's not thrilling to be highly unenthusiastic on a great company, but that's what I did when I turned negative on Johnson . . .
Posted on 2/20/18
Celgene's Otezla-Colitis Story; Implications For Other Biotechs
IntroductionCelgene (CELG) is back to 2014 levels, closing Friday at $96.14. It first reached this price in August 2014. Yet I just want to sit with . . .
Posted on 1/11/18
Celgene Tries To Rejoin The Party
BackgroundCelgene (CELG) has rejoined the group of biotechs trading at the same price they first reached when ascending to new heights in 2014. At $105-106 as . . .
Posted on 12/20/17
Teva's Tough Hanukah: Updated Analysis
Introduction: TEVA has an unhappy HanukahWhen you've been a corporate schlemiel, lumps of coal (or the equivalent) may be what you get under the Hanukah bush . . .
Posted on 12/1/17
Regeneron - An Update: Buying Into The Fear
Background - remembrance of growth pastWhen a former high growth stock, with high valuation to match, begins to look like a value stock, often it pays, . . .
Posted on 11/27/17
How Soros And Buffett Inform An Updated View Of Trading Apple
Introduction - looking for alpha in all the right places (I hope)There's a potential bullish set-up in Apple (AAPL) right now that reminds me of thoughts . . .
Posted on 11/14/17
GE: Jack Welch Returns, Maybe Better Than Ever
Background - my evolution on GEJust a brief mention of my published points of view on GE (GE). After this year's Q1 earnings release, with the . . .
Posted on 11/3/17
Teva's Q3 And Crash: A Bear Reviews And Updates The Story
IntroductionAn explanation of why I write bearish articles on a number of companies is in order. I am a long-only investor. That may change if I . . .
Posted on 10/27/17
Celgene Crashes: A Reassessment
IntroductionNow that Celgene (CELG) has plunged in short order from an all-time high above $145 to below $100 as I write this intra-day Thursday, it's time . . .
Posted on 10/19/17
J&J: Unattractive
Why Q3 was a downerJohnson & Johnson (JNJ), a Dow 30 (DIA) stock and one of only two remaining AAA-rated credits among US-based corporations, reported earnings . . .
Posted on 10/6/17
Teva Might Be Getting Sicker As The Stock Drops
Teva's problem - Bad can get worseSometimes a stock is a better sell at a lower price than it was at the prior, higher price range; . . .
Posted on 9/25/17
J&J: Thoughts On Sirukumab And Other Problems
BackgroundIn my 8 articles on Johnson & Johnson (NYSE:JNJ) over the past 3 1/2 years, I have alternated between liking the stock and being neutral on . . .
Posted on 9/25/17
J&J: Thoughts On Sirukumab And Other Problems
Johnson & Johnson has become an expensive stock with limited growth prospects.Its appeal has centered around dividend growth prospects (aka bond substitute) anchored by an AAA . . .
Posted on 9/8/17
Thoughts On Celgene Rising Despite Negative News Today
Introduction - Celgene not as strong as Hurricane Irma, but pretty strong nonethelessThe biotech I have championed most strongly for the past 11 months, Celgene (NASDAQ:CELG), . . .
Posted on 8/14/17
Vertex Pharmaceuticals May Be Turning Some Major Corners
Introduction - Rationale for the articleOne of the several smaller but commercial-sized biotechs that has been around for decades but is yet to truly emerge as . . .
Posted on 8/7/17
Bristol-Myers Squibb: A Combined Value And Growth Story
BackgroundBristol-Myers Squibb (NYSE:BMY) was formed from a merger of two old-line pharma companies more than a quarter century ago. At the time, it was a powerhouse. . . .
Posted on 8/7/17
Teva And The Other Generics Stocks: Fair Value Discussion
BackgroundWith the collapse in Teva (TEVA) stock and other generics last week, I have reviewed my articles and find that the last time I commented on . . .
Posted on 8/3/17
Pfizer: Why The Stock May Get Interesting Again
BackgroundPfizer (PFE) delivered an in-line Q2, with consensus Street forward estimates for this year and next changing little. Rather than get into the details of a . . .
Posted on 7/20/17
J&J: Some Good News, But Here's Why It's Dropped A Level Or Two
IntroductionJohnson & Johnson (JNJ) had an unimpressive quarter and guided down. Yet the stock moved up, participating in the strong global rally that equities are enjoying.I'd . . .
Posted on 6/2/17
Celgene Defends The Stock With Positive Portents
Celgene (NASDAQ:CELG) fights the sell-offThis CEO performance shows that CELG has my sort of management team. That's in contrast to the CEO of a different biotech . . .
Posted on 5/24/17
Celgene - Crippled By Its Pipeline MS Drug? Or, Buy The Dip?
IntroductionSometimes P/Es shrink, and then the bottom falls out of the business or the sector. Sometimes it's a buying opportunity. Mr. Market does not tell you . . .
Posted on 5/11/17
Bristol-Myers Squibb: A Deep Dive Finds Some Pearls
IntroductionIt's one thing to speculate on takeovers. It's another to have a takeover merely as a kicker, with a strong company and a reasonably valued stock. . . .
Posted on 5/1/17
Celgene: A Reanalysis Based On Q1 Results And Guidance
IntroductionCelgene (NASDAQ:CELG), one of the great successes in all of global business for the past 20 years, reported Q1 results Thursday and provided a business update. . . .
Posted on 4/24/17
GE: Another IBM
GE as another IBMSometimes things come around with just the name changing.For example, here is the lead company-specific article on Yahoo! Finance (NASDAQ:YHOO) Friday afternoon: General . . .
Charlotte Raleigh
